Apnimed

39 John F Kennedy Street Cambridge MA 02138 US

JOBS

IN THE PRESS

Genetown

Apnimed to Participate in Upcoming October Investor Conferences

October 11, 2023

·

3 min read

Genetown

American Journal of Respiratory and Critical Care Medicine Publishes Full, Positive Results of Apnimed’s MARIPOSA Study on AD109, an Investigational Oral Drug for Obstructive Sleep Apnea

October 10, 2023

·

7 min read

Genetown

Apnimed Adds Independent Director Paul Fonteyne, MS, MBA to Board of Directors

October 2, 2023

·

4 min read

Drug Development

Apnimed Announces First Patient Dosed in LunAIRo, the First Phase 3 Clinical Study of AD109, a Potential Nighttime Oral Treatment for Obstructive Sleep Apnea

September 21, 2023

·

5 min read

Drug Development

Apnimed Appoints John Yee, MD, MPH, as SVP, Medical Affairs

September 18, 2023

·

4 min read

Drug Development

Apnimed to Present New Data on Investigational Oral Therapies for Obstructive Sleep Apnea at ERS International Congress 2023

September 6, 2023

·

4 min read

Genetown

APNIMED to Participate in Upcoming Investor Conferences in September 2023

August 30, 2023

·

3 min read

Genetown

Fierce Biotech Names Apnimed a 2023 “Fierce 15” Biotech Company

August 28, 2023

·

4 min read

Genetown

APNIMED to Participate in the 43rd Annual Canaccord Genuity Global Growth Conference

August 1, 2023

·

3 min read

Genetown

Apnimed to Participate in the William Blair Virtual Conference: Transitioning Biotech Breakthroughs to Commercial Success

July 12, 2023

·

3 min read